NMR-based metabolomics identifies patients at high risk of death within two years after acute myocardial infarction in the AMI-Florence II cohort.
Alessia VignoliLeonardo TenoriBetti GiustiPanteleimon G TakisSerafina ValenteNazario CarrabbaDaniela BalziAlessandro BarchielliNiccolò MarchionniGian Franco GensiniRossella MarcucciClaudio LuchinatAnna Maria GoriPublished in: BMC medicine (2019)
For the first time, metabolomic profiling technologies were used to discriminate between patients with different outcomes after an acute myocardial infarction. These technologies seem to be a valid and accurate addition to standard stratification based on clinical and biohumoral parameters.
Keyphrases
- left ventricular
- acute myocardial infarction
- heart failure
- end stage renal disease
- high resolution
- newly diagnosed
- ejection fraction
- magnetic resonance
- prognostic factors
- percutaneous coronary intervention
- single cell
- gene expression
- coronary artery disease
- patient reported outcomes
- atrial fibrillation
- dna methylation